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Critical role for CCR5 in the function of donor CD4CD25 regulatory T cells
during acute graft-versus-host disease
ChristianA. Wysocki, Qi Jiang, Angela Panoskaltsis-Mortari, PatriciaA. Taylor, Karen P. McKinnon, Lishan Su, Bruce R. Blazar, and
Jonathan S. Serody
CD4CD25 regulatory T cells (Tregs) have
been shown to inhibit graft-versus-host
disease (GVHD) in murine models, and
this suppression was mediated by Tregs
expressing the lymphoid homing mole-
cule L-selectin. Here, we demonstrate that
Tregs lacking expression of the chemokine
receptor CCR5 were far less effective in
preventing lethality from GVHD. Survival
ofirradiatedrecipientanimalsgiventrans-
plants supplemented with CCR5/ Tregs
was signiﬁcantly decreased, and GVHD
scores were enhanced compared with
animals receiving wild-type (WT) Tregs.
CCR5/Tregswerefunctionalinsuppress-
ing T-cell proliferation in vitro and ex
vivo. However, although the accumula-
tion of Tregs within lymphoid tissues dur-
ing the ﬁrst week after transplantation
was not dependent on CCR5, the lack of
function of CCR5/ Tregs correlated with
impaired accumulation of these cells in
the liver, lung, spleen, and mesenteric
lymph node, more than one week after
transplantation. These data are the ﬁrst to
deﬁnitively demonstrate a requirement
for CCR5 in Treg function, and indicate
that in addition to their previously deﬁned
role in inhibiting effector T-cell expansion
in lymphoid tissues during GVHD, later
recruitment of Tregs to both lymphoid tis-
sues and GVHD target organs is impor-
tant in their ability to prolong survival
afterallogeneicbonemarrowtransplanta-
tion. (Blood. 2005;106:3300-3307)
© 2005 by TheAmerican Society of Hematology
Introduction
Acute graft-versus-host disease (GVHD) is a severe and potentially
fatal complication of allogeneic bone marrow transplantation
(allo-BMT). Acute GVHD is caused by mature donor T cells that
recognize alloantigens presented initially by host antigen present-
ing cells (APCs).1,2 Our group has demonstrated that the accumula-
tion of donor T cells during the peritransplantation period takes
place primarily in lymphoid tissues, followed by recruitment to
parenchymal tissues such as the gastrointestinal (GI) tract, liver,
lung, and skin.3 We and others have recently demonstrated that
eliminating expression of the chemokine receptor CCR5 from
donor T cells in an experimental GVHD model resulted in
exacerbated GVHD and increased T-cell inﬁltration of the liver
and lung in lethally irradiated recipient animals.4,5 These data
suggested that the primary role for CCR5 during GVHD in
conditioned transplant recipients is not to direct effector-cell
recruitment as originally hypothesized, but to down-modulate
target organ inﬂammation.
Chemokines are predominantly 8-kDa to 12-kDa chemotactic
proteins, which bind a family of 7-transmembrane–spanning G
protein–coupled receptors, and function primarily in leukocyte
migration (reviewed in Moser et al6). The chemokine receptor
CCR5 is expressed on activated T helper-1/T cytotoxic-1 (TH1/
TC1) T cells, natural killer (NK) cells, macrophages, and dendritic
cells.7 The ligands for this receptor, CCL3, CCL4, and CCL5, are
expressed at sites of inﬂammation during acute GVHD.4,8-11 CCR5
may play a role in directing effector cells to sites of inﬂamma-
tion.12-15 Interestingly however, multiple studies in CCR5-deﬁcient
mice, in addition to our GVHD studies, demonstrate enhanced
cell-mediated immune responses during pathogen infection,16-18
delayed-type hypersensitivity,19 and tumor vaccination,20 suggest-
ing an immunoregulatory role for CCR5.
Within the past decade, CD4CD25 regulatory T cells (Tregs)
have been recognized as important mediators of peripheral toler-
ance, and deﬁciency of this population is associated with autoim-
mune inﬂammation, including type I diabetes,21-23 gastritis,24
inﬂammatory bowel disease,25 and thyroiditis24 in several murine
models. Tregs inhibit T-cell activation, proliferation, and effector
function (reviewed in Piccirillo and Shevach26). Tregs are also
capable of inhibiting allogeneic T-cell responses, such as skin and
solid organ allograft rejection.27-30Treg-mediated inhibition of acute
GVHD has been demonstrated by our group and others.31-37 The
gene FoxP3, encoding the forkhead family transcription factor
Scurﬁn, is constitutively expressed by Tregs, and is crucial in the
development of their suppressive phenotype.38-44
Our group and others have demonstrated the suppression of
T-cellexpansionwithinlymphoidtissuesduringGVHDbyTregs.45,46
The presence of Tregs has been demonstrated within parenchymal
organs such as the pancreas21,47 and lung,41 at sites of infection,48-51
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sites has been shown to impact local inﬂammation. Although a
number of studies have demonstrated chemokine receptor expres-
sion and responsiveness of Tregs to chemokines,22,53,55-59 no study
has deﬁnitively demonstrated a role for proinﬂammatory chemo-
kine receptors in Treg function.Accumulation of FoxP3-expressing
cells within cardiac allografts was recently shown to be dependent
on CCR4 expression by recipient mice.30 However, a direct
requirement for CCR4 expression by Tregs was not demonstrated.
Here we show that the expression of CCR5 by donor Tregs is
critical for their ability to suppress lethality due to acute GVHD.
The inability of CCR5/ Tregs to suppress GVHD lethality
correlates with reduced accumulation of CCR5/ as compared




Mice used for transplantation were described previously.4,60 Within each
experiment, all recipient mice were the same sex and age, which ranged
from 6 to 10 weeks. Donor mice were gender-matched to recipients, and
ranged from 6 to 13 weeks of age. Scurfy mice (Sf/), which have been
described,61 were a kind gift from Dr Virginia Godfrey. All animal
experiments were performed in accordance with protocols approved by the
University of North Carolina InstitutionalAnimal Care and Use Committee.
Cell isolations
T-cell–depleted bone marrow (TCD-BM) and whole splenic T cells were
prepared from WT donors as described.4 CD25 splenic T cells were
prepared from WT or CCR5/ donors as follows: splenic T cells were
isolated using Mouse T-cell Immunocolumns (Cedarlane Laboratories,
Hornby, ON, Canada), according to the manufacturer’s protocol, and
stained with anti-CD25-biotin (clone 7D4; BD Biosciences Pharmingen,
San Diego, CA), followed by streptavidin–phycoerythrin (PE). Cells were
labeled with anti-PE microbeads (Miltenyi Biotech, Gladbach, Germany),
and CD25 cells depleted following methods from the manufacturer
(Miltenyi Biotech). The depletion of CD25 T cells was more than 90%. In
some experiments, CD4CD25 Tregs were puriﬁed by isolating CD25
cells using the approach described above, staining with anti-CD4-Cy5
(clone RM4-5; BD Biosciences Pharmingen), and sorting the CD4CD25
cells to 90% to 97% purity using a MoFlo high speed cell sorter
(Cytomation, Fort Collins, CO). In most experiments, Tregs were puriﬁed
from the spleens of donor mice, to 90% to 95% purity, using a previously
described column-puriﬁcation protocol.45
Bone marrow transplantation
Irradiation, transplantation, and housing of mice were performed as
described.4 Transplant recipients received 3  106 TCD WT bone marrow
cells and 5  106 CD25-depleted (CD25) T cells (WT or CCR5/). For
survival studies, some groups received transplants supplemented with Tregs
from WT or CCR5/ donors. The dose of Tregs administered for survival
and GVHD grading studies was 1.5  106 in experiments using Tregs sorted
by ﬂuorescence-activated cell sorting (FACS), and 2.75  106 in experi-
ments using column-puriﬁed Tregs. For in vivo migration studies, recipients
were given transplants containing WT TCD-BM and either WT whole
splenicTcells orWTCD25Tcells, alone or supplemented with 0.5  106
to 1.5  106 Tregs puriﬁed from WT or CCR5/ donors. In most migration
studies, Treg donors were WT/enhanced green ﬂuorescent protein (eGFP)
and CCR5//eGFP.
GVHD grading
Mice were observed twice weekly and GVHD evaluated using a published
clinical scoring system.62
Isolation of leukocytes from tissues
Isolation of total inﬁltrating leukocytes from target organs has been
described previously.4 To purify donor cell inﬁltrates, the total organ
leukocytes were stained with anti-H2Kd-PE (clone SF1-1.1; BD Bio-
sciences Pharmingen), followed by incubation with anti-PE microbeads
(Miltenyi Biotech), and depletion of H2Kd-expressing host cells according
to the manufacturer’s instructions. The remaining cells were more than
95% donor.
Antibodies and ﬂow cytometry
Monoclonal antibodies used for FACS were obtained from BD Biosciences
Pharmingen and included anti-H2Kd-PE (or a biotinylated version) (SF1-
1.1–mouse IgG2a-kappa), anti-mCD4-PerCP (RM4-5–rat IgG2a-kappa),
anti-CD25-biotin (clone 7D4–rat IgM). Isotype controls were obtained
from BD Biosciences Pharmingen. To generate polyclonal antimurine
Scurﬁn antibody, rabbits were immunized with the peptide CLLGTRGSG-
GPFQGRDLRSGAH from the N-terminus of the murine Scurﬁn protein
(Proteintech Group, Chicago, IL). Polyclonal antibody was afﬁnity-puriﬁed
using the immunizing peptide via the SulfoLink Kit (Pierce Biotechology,
Rockford, IL). Speciﬁcity of the puriﬁed antibody was conﬁrmed by
Western blot and FACS analysis (Figure S1, available on the Blood website;
see the Supplemental Figure link at the top of the online article). For
intracellular staining, BD FACS permeabilizing solution 2 (BD Bio-
sciences Pharmingen) was used according to the manufacturer’s proto-
col. Cells were stained with antimouse Scurﬁn antibody or normal rabbit
IgG (Caltag Laboratories, Burlingame, CA), followed by goat anti–
rabbit IgG (HL)–PE (Caltag). Flow cytometry and analysis were
performed as previously described.4
Treg culture and chemotaxis assay
Tregs and CD4CD25Tcells were isolated fromWTand CCR5/ donors,
and 1  106 cells were activated and cultured using immobilized anti-CD3
antibody and interleukin 2 (IL-2).33 After 5 days in culture, cells were
counted and chemotaxis assays performed to assess migration to 1, 10, 100,
and 1000 ng/mL recombinant murine CCL3, CCL4, or CCL5 (Peprotech,
Rocky Hill, NJ) as previously described.4
Real-time reverse transcriptase–polymerase chain reaction
(RT-PCR) analysis of CCR5 and FoxP3 expression
Total RNA isolation, synthesis of cDNA, and quantitative real-time
RT-PCR (QPCR) were performed using a previously described method.4
Primers and probe for murine CCR5 were as follows (5 to 3): CCR5
forward: GACTCTGGCTCTTGCAGGAT; CCR5 reverse: GCCGCAATT-
TGTTTCACAT; probe: TCAAGGGTCAGTTCCGACCTATAGC.
Murine FoxP3 and 18S rRNAprimers and probes have been previously
described.4,40 Copies of CCR5 or FoxP3 mRNA in each sample were
calculated using standard curves, and were normalized by dividing by the
copies of 18S rRNAand multiplying by 104.
In vitro suppression assays
Allogeneic stimulators were prepared from spleen cell suspensions of
B6D2 mice, depleted of T cells using anti-CD90 magnetic beads (Miltenyi
Biotech), and irradiated with 2100 cGy from a 137Cs source. Stimulators
(1  105) were incubated with responders (WT CD4CD25 T cells,
1  105) and various ratios of Tregs from WT or CCR5/ donors. Cultures
were incubated for 5 days at 37°C and 1 Ci (0.037 MBq) 3H-thymidine
was added for the last 16 hours of culture. Incorporation of 3H-thymidine
was assessed as described.4 In other experiments, a previously described
protocol was used to measure Treg-mediated suppression.63 To measure
suppression by Tregs sorted from GVHD target organs, cultures were
prepared as above, using allogeneic stimulators (2.5  104), and WT
CD4CD25 responders (2.5  104). Inﬁltrating leukocytes were isolated
from GVHD target organs and the GFP-expressing CD4 Tregs or
CD4CD25 T cells were sorted using a MoFlo high-speed cell sorter
(Cytomation). Tregs or CD4CD25 T cells were added to cultures at the
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Apoptosis assay
Tregs were column-puriﬁed from WT or CCR5/ donors, activated, and
expanded in culture.Aliquots of cells were taken on days 3 and 5 of culture,
and assessed for apoptosis using anAnnexinVApoptosis Detection kit (BD
Biosciences Pharmingen), according to the manufacturer’s instructions.
Statistical analysis
Estimates of the probability of survival for all groups were determined
using the method of Kaplan and Meier.64 Mean survival times were
compared using the rank sum test. Cells migrating to chemokines were log
transformed and compared by Student t test. Clinical scores, cell inﬁltra-
tion, and FoxP3 expression were compared by Student t test. For all tests, P
values less than or equal to .05 were considered signiﬁcant.
Results
Functional expression of CCR5 on CD4CD25 Tregs after
activation through the T-cell receptor
Initially, we assessed the expression of CCR5 on Tregs, and the
ability of those cells to migrate in response to CCR5-binding
chemokines in vitro. We found that CD4CD25 T cells isolated
from the spleens of unmanipulated C57BL/6 (WT) mice did not
express signiﬁcant levels of CCR5 mRNA. However, after poly-
clonal activation by culturing on immobilized anti-CD3 monoclo-
nal antibody in the presence of IL-2, expression of CCR5 mRNA
was strongly upregulated on WT Tregs (Figure 1A). We observed
signiﬁcant migration of WT Tregs in response to the CCR5-binding
chemokines CCL3, CCL4, and CCL5. Responsiveness of activated
Tregs to a physiologic concentration (10 ng/mL) of CCL4 and CCL5
was signiﬁcantly greater than that of similarly activated
CD4CD25 T cells, with a strong trend for increased responsive-
ness to CCL3 (Figure 1B). Similar trends were observed at
chemokine doses of 1 ng/mLand 100 ng/mL(data not shown).Tregs
isolated from CCR5/ mice did not migrate in response to the
CCR5-speciﬁc chemokine CCL4 (Figure 1C), conﬁrming that the
responsiveness of WT Tregs to this chemokine was CCR5 speciﬁc.
Activated WT Tregs that migrated in response to CCL4 expressed
similar levels of FoxP3 mRNA, compared with Tregs evaluated
prior to the migration assay (Figure 1D), demonstrating that CCL4
induces the migration of FoxP3-expressing Tregs.
CCR5 expression on Tregs is critical for GVHD suppression
To address the role of CCR5 expression in the function of donor
Tregs in vivo during acute GVHD, we used a parent-to-F1 (ﬁrst ﬁlial
generation) murine GVHD model similar to that used in our
previous study.4 Lethally irradiated B6D2 recipients were given
transplants consisting of 3  106 WT TCD-BM cells plus 5  106
CD25-depleted (CD25) T cells from WT or CCR5/ mice.All of
these recipients suffered GVHD-related mortality. However, unlike
our previous ﬁndings using whole (Treg-replete) splenicTcells,4 we
did not observe earlier mortality in recipients of CCR5/ CD25
T cells (Figure 2A). Median survival of recipients of WT or
CCR5/ CD25 T cells was 17 and 19 days, respectively
(P  .23), suggesting that the enhanced GVHD found previously
using CCR5/ T cells may be due to impaired in vivo function
of CCR5/ Tregs.
To more speciﬁcally assess differences in the ability of WT and
CCR5/ Tregs to inhibit GVHD, we added back WT or CCR5/
Figure 1. Functional expression of CCR5 on Tregs. (A) QPCR assessment of
CCR5 expression in column-puriﬁed Tregs and CD4CD25 T cells from WT (f) and
CCR5/ (o) mice. Shown is CCR5 expression in freshly isolated cells, and cells
cultured as in “Materials and methods.” Data are mean  the standard error of the
mean (SEM). (B) WT Tregs (f) and CD4CD25 T cells (u) were cultured as in panel
A, and migration in response to 10 ng/mL CCL3, CCL4, and CCL5 was determined.
Data are mean  SEM. *P 	 .05. (C) Chemotaxis of WT (f) and CCR5/ (o)T regs
and CD4CD25 T cells, cultured as above, in response to 100 ng/mL CCL4. Data
are mean  SEM. (D) QPCR analysis of FoxP3 mRNA expression in cultured WT
Tregs and CD4CD25 T cells prior to chemotaxis and in cells that migrated in
response to 100 ng/mLCCL4. Data are mean  SEM.
Figure 2. CCR5 deﬁciency impairs the ability of Tregs
to suppress GVHD morbidity and mortality. (A) Sur-
vival of lethally irradiated B6D2 recipients of allogeneic
BMT consisting of WT TCD-BM and CD25-depleted
(CD25) T cells from WT or CCR5/ donors. In some
groups, mice received WT TCD-BM and WT CD25 T
cells, plus Tregs from WT or CCR5/ donors. Figure
represents data pooled from 2 separate experiments
yielding similar results. For WTCD25,n 10; CCR5/
CD25,n 10; WT CD25 plus WT Tregs,n 8; WT
CD25 plus CCR5/ Tregs,n  8. (B) Clinical GVHD
scores of recipients above were evaluated at the time
points shown. Data represent mean score  SEM at
each time point.
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their ability to prevent GVHD lethality and reduce signs of
GVHD-related morbidity (Figure 2A-B). Adding WT Tregs to
transplants was highly effective in preventing GVHD lethality, as
median survival increased from 17 days in mice receiving WT
CD25 T cells alone, to 59 days (P  .002), with 50% of those
mice surviving until termination of the experiment on day 75. This
correlated with a signiﬁcant decrease in clinical GVHD score
compared with mice receiving WT CD25 T cells alone, starting
one week after transplantation and continuing throughout the
course of the experiment. In contrast, adding CCR5/ Tregs did not
prevent lethality, as only 12.5% of recipients survived through day
75. Furthermore, adding CCR5/ Tregs was signiﬁcantly less
effective in prolonging median survival time compared with adding
WT Tregs (P  .02). Adding CCR5/ Tregs decreased the clinical
score of GVHD in the ﬁrst 4 weeks after transplantation, compared
with control mice receiving WT CD25 T cells alone. However,
by day 30 and for the remainder of the experiment, clinical
scores in mice receiving CCR5/ Tregs were similar to the peak
scores found in the control group. These data demonstrated that
CCR5/ Tregs were signiﬁcantly impaired in their ability to
inhibit GVHD in vivo.
CCR5 expression is not required for FoxP3 expression,
development of suppressive function, or expansion and
survival of activated Tregs
We next sought to address the mechanism for the impaired in vivo
function of CCR5/ Tregs during GVHD. We compared the
suppressive abilities ofTregs isolated from the spleens of unmanipu-
lated WT and CCR5/ mice using previously published in vitro
assays.34,63 CD4CD25 T cells were present in comparable
proportionsinthespleensandperipherallymphnodesofunmanipu-
lated CCR5/ and WT mice (Figure 3A). Tregs from CCR5/
mice were comparable to those from WT mice in their ability to
suppress the proliferation of WT CD4CD25 responder cells in
response to irradiated B6D2 allogeneic stimulators at all Treg-to-
responderratios(Figure3B).FoxP3mRNAexpressioninCCR5/
Tregs was comparable to that in WT Tregs (Figure 3C). We also
assessed the ability of WT and CCR5/ Tregs to proliferate and
undergo apoptosis when activated and expanded in culture. A
similar net expansion of CCR5/ and WT Tregs was found over 5
days in vitro, and similar proportions of WT and CCR5/ Tregs
underwent apoptosis at days 3 and 5 in culture (data not shown).
Thus, CCR5 does not play a critical role in regulating the
development, suppressive function, or FoxP3 gene expression of
Tregs, and the absence of CCR5 does not impair the proliferation or
survival of Tregs in vitro.
CCR5 expression on Tregs is required for inﬁltration of target
organs during GVHD
Previous studies have demonstrated that Treg function during
GVHD was dependent on the expression of L-selectin (CD62L) by
Tregs.45,46 L-selectin expression on the surface of WT and CCR5/
Tregs and conventional CD4 T cells was similar both in freshly
isolated cells and cells isolated during the ﬁrst week after transplan-
tation (data not shown).
We assessed the accumulation of WT and CCR5/ Tregs in
lymphoid tissues after transplantation by purifying CD4CD25
Tregs from WT/eGFP or CCR5//eGFP transgenic mice and
adding eGFP-expressing Tregs to transplants containing WT
TCD-BM and WT whole splenic T cells. On day 5 after transplan-
tation, no signiﬁcant differences were observed in the numbers of
GFP-positive CD4 T cells in spleen or mesenteric lymph node
(MLN) of mice receiving WT or CCR5//eGFP Tregs (Figure 4).
Additionally, no signiﬁcant differences were observed in the
numbersofWT/eGFPandCCR5//eGFPTregsinﬁltratingtheliver
and lung. Similar results were found when assessing the accumula-
tion of WT or CCR5/ Tregs in the spleen, MLN, liver, and lung on
day 7 after transplantation (data not shown). Thus, the absence of
CCR5 on Tregs did not affect the accumulation of these cells in
either lymphoid tissues or GVHD target organs in the ﬁrst week
after transplantation.
The accumulation of Tregs in GVHD target organs in the second
week after transplantation was dependent on CCR5. For these
experiments, recipients underwent transplantation as described
above, except that CD25-depleted T cells as opposed to whole
splenic T cells were given. CCR5//eGFP Treg numbers were
lower than WT/eGFP Treg numbers in both the liver and spleen on
Figure 3. CCR5 deﬁciency does not affect the proportions of Tregs in the
periphery, the suppressive function of Tregs, FoxP3 expression, proliferation, or
survival. (A) CD4CD25 T cells in spleens, and inguinal (ILNs) and mesenteric
lymph nodes (MLNs) from male WT and CCR5/ mice. Shown are cells within the
live lymphocyte gate. Data are representative of 2 organs per group. (B) Suppression
of WT responder cell proliferation in response to B6D2 alloantigen by WT (f) and
CCR5/ (o)T regs was assessed as described in “Materials and methods.” Data
represent mean  SEM. *P  .05. (C) FoxP3 expression in WT(f) and CCR5/ (o)
Tregs and CD4CD25, cultured as described in “Materials and methods,” was
assessed by QPCR. Data represent mean  SEM.
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in CCR5/ versus WT GFPCD4 T-cell accumulation were
observed in the MLN at this time (data not shown).
To address the concern that the GFP cells evaluated could be
contaminated with rapidly proliferating non-Tregs,41,43 we quantiﬁed
the expression of FoxP3 in donor cell inﬁltrates from speciﬁc
tissues isolated from mice at day 10. We found signiﬁcant levels of
FoxP3 mRNAexpression in donor cells isolated from target organs
only whenTregs were added to the transplants, conﬁrming the utility
of this approach to assess Treg accumulation. FoxP3 mRNA
expression in donor cell inﬁltrates isolated from the livers of mice
receiving CCR5//eGFP Tregs was lower than that in mice
receiving WT Tregs. Decreased FoxP3 expression correlated di-
rectly with the reduction in CCR5/ GFPCD4 T-cell numbers in
livers, demonstrating that the accumulation of CCR5//eGFPTregs
at this site was signiﬁcantly less than that ofWT/eGFPTregs (Figure
5B). FoxP3 mRNAlevels were also reduced in donor cell inﬁltrates
from the lungs of mice receiving CCR5/ Tregs as compared with
WT Tregs (Figure 5C). Interestingly, although we had observed a
signiﬁcant reduction in GFPCD4 T-cell numbers in the spleens of
mice receiving CCR5//eGFP Tregs as compared with WT/eGFP
Tregs, FoxP3 mRNAlevels were not signiﬁcantly different between
these 2 groups (Figure 5B).
We assessed FoxP3 expression in donor cells inﬁltrating the
liver, spleen, and MLN at days 13 and 16 after transplantation
(Figure 5D). At days 13 and 16, FoxP3 expression in donor cell
inﬁltrates isolated from liver, as well as spleen and MLN, was
lower when mice received CCR5//eGFP Tregs, as compared with
WT/eGFP Tregs. Importantly, this did not correlate with an overall
reduction in GFP-expressing cells in GVHD target tissues over
time, as the number of both WT and CCR5/ GFPCD4 T cells
inﬁltrating liver (CCR5/ 167% increase; WT 235%) and spleen
(CCR5/ 135%; WT 91%) increased between days 10 and 13.
Thus, although CCR5 expression by Tregs was not required for their
accumulation in lymphoid tissues during the ﬁrst week after
transplantation, accumulation of CCR5/Tregs in lymphoid tissues
was lower than WT Tregs after day 10. The discrepancy between
GFPCD4 T-cell numbers and FoxP3 mRNAexpression in donor
cells isolated from spleens at day 10 suggested that a proportion of
the GFPCD4 T cells inﬁltrating the spleens were non-Treg.
To resolve the discrepancy between GFP Treg numbers and
FoxP3 expression data, we used a novel anti-Scurﬁn polyclonal
antibody generated by our group (Figure S1) to determine the total
number of GFPCD4Scurﬁn cells inﬁltrating the spleen and
liver 10 days after transplantation (Figure 5E). We found no
signiﬁcant difference in GFPCD4Scurﬁn cell numbers in the
spleens of mice receiving WT/eGFP or CCR5//eGFP Tregs, but a
signiﬁcant 3-fold reduction, which was similar to the difference in
FoxP3 mRNAexpression, in the number of these cells in the livers
of mice receiving CCR5//eGFP compared with WT/eGFP Tregs.
Thus, measurement of FoxP3 mRNA expression in donor-cell
inﬁltratesisolatedfromtargetorgans,orﬂowcytometricdetermina-
tion of the frequency of FoxP3 cells, are more rigorous methods
Figure 4. Inﬁltration of WT and CCR5/ Tregs, measured by quantitation of
eGFPCD4 cell inﬁltrates in lymphoid tissues and target organs on day 5 after
transplantation. Lethally conditioned B6D2 mice received transplants containing
WT TCD-BM and WT whole splenic T cells, with FACS-sorted WT/eGFP (f)o r
CCR5//eGFP (o)T regs added. The numbers of eGFPCD4 cells inﬁltrating the
organs shown were determined by ﬂow cytometry on day 5 after transplantation.
n  4 mice/group. Data represent mean  SEM.
Figure 5. Quantitation of FoxP3 expression in donor
cells inﬁltrating lymphoid tissues and target organs
on days 10, 13, and 16 after transplantation. (A)
Transplants consisted of WT TCD-BM and WT CD25 T
cells, with column-puriﬁed WT/eGFP (f) or CCR5//
eGFP (o)T regs. The numbers of eGFPCD4 cells
inﬁltrating the spleen and liver were determined by ﬂow
cytometry on day 10. These data are representative of 2
similar experiments. *P 	 .05 (B) FoxP3 expression in
donor cell inﬁltrates puriﬁed on day 10 from spleens and
livers of transplant recipients receiving TCD-BM and WT
CD25 T cells, either alone (u) or with column-puriﬁed
Tregs from WT/eGFP (f) or CCR5//eGFP (o) donors.
Donor cell inﬁltrates were pooled from 3 mice per group.
Data shown are representative of 2 separate experi-
mentsyieldingsimilarresults.*P 	 .05.(C)FoxP3expres-
sion in donor cell inﬁltrates puriﬁed on day 10 from lungs
of mice transplanted as above. Donor cell inﬁltrates were
pooled from 3 mice per group. (D) FoxP3 expression in
donor cell inﬁltrates puriﬁed on days 13 and 16 from
spleens, livers, and MLNs of recipient mice transplanted
as in panel B. Donor cell inﬁltrates were pooled from 4
mice per group on day 13 and from 3 mice receiving
WT/eGFP Tregs and 2 mice receiving CCR5//eGFP
Tregs on day 16. (E) Mice underwent transplantation as in
panelA, and intracellular Scurﬁn analysis was performed
on leukocytes pooled from the spleen or liver of 3 mice
per group on day 10. Total GFPCD4Scurﬁn cells per
organ were calculated by multiplying the total number of
GFPCD4 cells in each organ, by the percent Scurﬁn.
Data shown are mean  SEM. *P 	 .05.
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CD4CD25 T cells. This observation is consistent with recent
data demonstrating that approximately 25% of CD4CD25 cells
from normal mice do not express FoxP3 protein, and in fact
proliferate when stimulated in vitro.41
WT and CCR5/ Tregs present in target tissues during GVHD
maintain their suppressive phenotype
We sought to determine whether the FoxP3-expressing Tregs
residing in target tissues during GVHD maintain their suppressive
phenotype. To accomplish this, we isolated GFP-expressing Tregs
from the spleens and livers of mice having received transplants
containingWTTCD-BM,WTCD25Tcells, and eitherWT/eGFP
or CCR5//eGFP Tregs, 14 days earlier. As a control, a group of
recipient mice received transplants containing CD4CD25Tcells
from WT/eGFP donors. Both WT/eGFP and CCR5//eGFP Tregs
effectively suppressed responder cell proliferation (Figure 6), when
sorted from either the spleen or the liver. GFP CD4CD25 T
cells isolated from the spleens of control mice did not suppress
responder cell proliferation. Thus, donor Tregs inﬁltrating both
lymphoid and extra-lymphoid GVHD target organs maintained
their suppressive phenotype through the ﬁrst 2 weeks after
transplantation. Furthermore, these data indicate that the lack of
function of CCR5/ Tregs in suppressing GVHD lethality was not
due to loss of the suppressive phenotype during GVHD in vivo.
Discussion
The function of naturally occurring CD4CD25 Tregs in modulat-
ing GVHD has been well documented.31-36,46 Our group and others
have shown previously that the ability of L-selectinHi Tregs to inhibit
effector T-cell expansion within secondary lymphoid tissues early
after allo-BMT correlated with their ability to suppress GVHD.45,46
Interestingly, here we demonstrate that recruitment of Tregs to sites
of inﬂammation and lymphoid tissues later after transplantation via
the chemokine receptor CCR5 is also crucial for the function of
these cells. This study provides the ﬁrst deﬁnitive demonstration of
a requirement for a chemokine receptor in the function of these
cells in vivo.
Previous studies have demonstrated that CCR5 expression by
Tregs is speciﬁc to a subset of Tregs, which preferentially inﬁltrate
extralymphoid sites and sites of inﬂammation.21,41 This Treg subset
has been shown to express a more activated phenotype. Our data
support the notion that CCR5 expression by Tregs requires an
activation stimulus. It is interesting to note that a number of studies
have demonstrated enhanced cell-mediated immune responses in
CCR5/ mice, including increased GVHD severity,4,5 tumor
immunity,20responsestopathogens,16-18anddelayed-typehypersen-
sitivity.19 Additionally, humans with the CCR5
32 mutation,
which reduces CCR5 expression on leukocytes,65 have a propensity
for autoimmune diseases of the liver and lung.66-68 Thus, CCR5
expression by Tregs may be important in suppression of inﬂamma-
tion in a speciﬁc subset of organs.
Our data suggest that CCR5 is not required for accumulation of
Tregs in lymphoid tissues during the ﬁrst 10 days after transplanta-
tion. Although we have demonstrated CCR5-ligand expression
within the spleen beginning early after transplantation in this
model,4 the similarity in WT and CCR5/ Treg numbers in spleen
and MLN during the ﬁrst 10 days after transplantation demon-
strates that the presence of Tregs in lymphoid tissues does not
initially depend on their expression of CCR5. Based on previous
studies, L-selectin, perhaps acting in concert with ligands that bind
to CCR7, directs the early homing of Tregs to lymphoid tissues after
transplantation.22,45,46
Previously, we demonstrated expression of the CCR5-ligands
CCL3 and CCL4 in the liver and lung during GVHD, which
reached peak levels between days 7 and 14.4 Here, although not
affected during the ﬁrst week, by 10 days after transplantation,
CCR5/ Treg inﬁltrates were signiﬁcantly lower than WT Tregs.
Lower CCR5/ Treg inﬁltration of the liver was also evident at
later time points. Thus, the time points at which target organ
inﬁltration by Tregs was affected by CCR5-deﬁciency correlated
with the kinetics of CCR5-ligand expression at these sites.
Decreased inﬁltration of CCR5/ Tregs in the liver and lung
correlated with increased total CCR5/ CD4 and CD8 T cells,
and increased tissue pathology found in our previous study at these
sites.4 Interestingly, on days 13 and 16, lower CCR5/ Treg
inﬁltration was observed in spleen and MLN as well. Thus,
although CCR5 does not direct the initial entry of Tregs into
lymphoid tissues after transplantation, at later time points activated
Tregs may recirculate to lymphoid tissues via CCL3, CCL4, or
CCL5 produced at these sites.
Reduced inﬁltration of CCR5/ Tregs, as compared with WT
Tregs, most likely reﬂects impairment in their migration in response
to ligands that bind to CCR5. Conceivably, defects in proliferation
or survival could be responsible for these ﬁndings, although we
were unable to demonstrate these in vitro. Comparable suppressive
function of CCR5/ and WT Tregs sorted from target organ
inﬁltrates on day 14 after transplantation is not consistent with a
greater fraction of CCR5/ Tregs undergoing apoptosis in target
tissues. Additionally, we found that the number of eGFP-
expressing cells in target organs increased over time in mice
receivingeitherWT/eGFPorCCR5//eGFPTregs,stronglysuggest-
ing that differential expansion or survival of CCR5//eGFPTregs is
not responsible for the differences observed.
We propose a bimodal model for the function of Tregs in
suppressing lethal acute GVHD. Early after transplantation, Tregs
Figure 6. CCR5/ and WT Tregs sorted from target organ–inﬁltrating cells are
suppressive in vitro. Lethally conditioned recipients were given transplants contain-
ing WT TCD-BM and WT CD25 T cells, with column-puriﬁed WT/eGFP (black bars)
or CCR5//eGFP (hatched bars) Tregs or with WT/eGFP CD4CD25 T cells (dark
gray bars). GFPCD4 cells were isolated from spleen and liver inﬁltrates by ﬂow
cytometric sorting on day 14, from 3 mice per group.These were used in the indicated
Treg/responder cell ratios in an in vitro suppression assay, as described in “Materials
and methods.” (Note: From previous work [Figure 5], a signiﬁcant proportion of
GFPCD4 T cells sorted from target tissues are FoxP3-negative cells. The indicated
ratios therefore overestimate Treg numbers and should not be compared to suppres-
sion by freshly isolated cells in Figure 3.)
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cells within lymphoid tissues. Activation of Tregs within lymphoid
tissues induces expression of CCR5. The presence of ligands for
CCR5 in target tissues, which are produced by inﬁltrating donor T
cells,69 would induce Treg migration to those sites and further limit
the local expansion and/or cytolytic effector function of alloreac-
tive T cells. Later, the expression of CCR5 may be crucial in the
migration of activated Tregs back to inﬂamed lymphoid tissues.
In conclusion, we have found that the expression of CCR5 on
donor Tregs is critical for their inﬁltration of GVHD target organs
later than one week after transplantation and eliminating expres-
sion of CCR5 from Treg-exacerbated GVHD in lethally condi-
tioned, MHC-mismatched recipients. Our ﬁndings suggest that the
CCR5
32 allele may be a predisposing factor for the occurrence of
lethal GVHD after allogeneic human stem cell transplantation in
recipients of myeloablative conditioning. Additionally, inhibition
of Treg migration may be clinically important in tumor immuno-
therapy, as migration ofTregs to the tumor may represent a barrier to
therapeutic efﬁcacy.53 We are currently investigating the impor-
tance of CCR5 in Treg-mediated tolerance in tumor models.
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